{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029221","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.392139+00:00","generated_at":"2026-06-04T23:55:24.733865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway","bullets":["Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.","GAAP R&D expenses $86.1M in FY2023 (including $11.8M stock-based comp); non-GAAP R&D $74.4M.","Pivotal Phase 3 OPERA-01 monotherapy trial initiated Q4 2023; top-line results expected in 2026.","Phase 2 study of palazestrant + ribociclib (60 patients) fully enrolled; data at ESMO Breast Cancer May 2024.","KAT6 inhibitor OP-3136 nominated as development candidate; IND filing expected late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029221","json":"https://secwatch.observer/filing/0000950170-24-029221.json","markdown":"https://secwatch.observer/filing/0000950170-24-029221.md","text":"https://secwatch.observer/filing/0000950170-24-029221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/olma-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:55:24.733865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a51ec1c1d028d6ca1d9c4bc88788238be3550c7","claim":"Olema Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss was $26.8 million.","evidence_excerpt":"Net loss was $26.8 million and $96.7 million for the quarter and year ended December 31, 2023, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss was $26.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aa09a93e5158cb107e38fc9d280540ff75faa7a5","claim":"Olema Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $96.7 million.","evidence_excerpt":"Net loss was $26.8 million and $96.7 million for the quarter and year ended December 31, 2023, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $96.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}